Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 724

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

MULTICENTER RANDOMIZED TRIAL COMPARING TACROLIMUS (FK506) AND CYCLOSPORINE IN THE PREVENTION OF RENAL ALLOGRAFT REJECTION1: A Report of the European Tacrolimus Multicenter Renal Study Group

Mayer, A. David, Dmitrewski, Jan, Squifflet, Jean-Paul, Besse, Tatjana, Grabensee, Bernd, Klein, Barbara, Eigler, Friedrich W., Heemann, Uwe, Pichlmayr, Rudolf, Behrend, Matthias, Vanrenterghem, Yves, Donck, Jan, van Hooff, Johannes, Christiaans, Maarten, Morales, Jose M., Andres, Amado, Johnson, Robert W.G., Short, Colin, Buchholz, Bernd, Rehmert, Nikola, Land, Walter, Schleibner, Stefan, Forsythe, John L.R., Talbot, David, Neumayer, Hans-H., Hauser, Ingeborg, Ericzon, Bo-G??ran, Brattstr??m, Christina, Claesson, Kerstin, M??hlbacher, Ferdinand, Pohanka, Erich · 1997 · Transplantation

Abstract

BACKGROUND: To confirm the results of a number of studies conducted in Europe, the United States, and Japan, this multicenter, randomized trial compared the 12-month efficacy and safety of tacrolimus- and cyclosporine-based immunosuppressive regimens in the prevention of renal allograft rejection. METHODS: A total of 448 renal transplant recipients were recruited from 15 centers and assigned to receive triple-drug therapy consisting of tacrolimus (n=303) or cyclosporine (n=145) in conjunction with azathioprine and low-dose corticosteroids. RESULTS: At 12 months after transplantation, tacrolimus therapy was associated with a significant reduction in the frequency of both acute (tacrolimus 25.9% vs. cyclosporine 45.7%; P<0.001 [absolute difference: 19.8%, 95% confidence interval: 10.0-29.6%]) and corticosteroid-resistant rejection (11.3% vs. 21.6%; P=0.001 [absolute difference: 10.3%, 95% confidence interval: 2.5-18.2%]). Actuarial 1-year patient (tacrolimus 93.0% vs. cyclosporine 96.5%; P=0.140) and graft survival rates (82.5% vs. 86.2%; P=0.380) did not differ significantly between the two treatment groups. Overall, the safety profiles of the tacrolimus- and cyclosporine-based regimens were quite comparable. Infections, renal impairment, neurological complications, and gastrointestinal complaints were frequently reported but were mostly reversible in both groups. Higher incidences of elevated serum creatinine, tremor, diarrhea, hyperglycemia, diabetes mellitus, and angina pectoris were reported in the tacrolimus treatment group, whereas acne, arrhythmia, gingival hyperplasia, and hirsutism were more frequent with cyclosporine treatment. CONCLUSIONS: The significant reduction in the incidence of episodes of allograft rejection observed with tacrolimus therapy may have important long-term implications given the prognostic influence of rejection on graft survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-199708150-00012

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 724

Metadata

Authors
Mayer, A. D., Dmitrewski, J., Squifflet, J.-P., Besse, T., Grabensee, B., Klein, B., Eigler, F. W., Heemann, U., Pichlmayr, R., Behrend, M., Vanrenterghem, Y., Donck, J., van Hooff, J., Christiaans, M., Morales, J. M., Andres, A., Johnson, R. W. G., Short, C., Buchholz, B., Rehmert, N., Land, W., Schleibner, S., Forsythe, J. L. R., Talbot, D., Neumayer, H.-H., Hauser, I., Ericzon, B.-G., Brattstr??m, C., Claesson, K., M??hlbacher, F., & Pohanka, E.
Venue
Transplantation
Published
1997-08
Volume
64
Issue
3
Pages
436-443
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2027371366
Cited by
724
References
17
FWCI
34.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MULTICENTER RANDOMIZED TRIAL COMPARING TACROLIMUS (FK506) AND CYCLOSPORINE IN THE PREVENTION OF RENAL ALLOGRAFT REJECTION1: A Report of the European Tacrolimus Multicenter Renal Study Group. https://app.cochat.ai/papers/10.1097/00007890-199708150-00012
The paper
Mayer, A. D., Dmitrewski, J., Squifflet, J.-P., Besse, T., Grabensee, B., Klein, B., Eigler, F. W., Heemann, U., Pichlmayr, R., Behrend, M., Vanrenterghem, Y., Donck, J., van Hooff, J., Christiaans, M., Morales, J. M., Andres, A., Johnson, R. W. G., Short, C., Buchholz, B., . . . Pohanka, E. (1997). MULTICENTER RANDOMIZED TRIAL COMPARING TACROLIMUS (FK506) AND CYCLOSPORINE IN THE PREVENTION OF RENAL ALLOGRAFT REJECTION1: A Report of the European Tacrolimus Multicenter Renal Study Group. Transplantation. https://doi.org/10.1097/00007890-199708150-00012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.